PMID- 21628884
OWN - NLM
STAT- MEDLINE
DCOM- 20111007
LR  - 20191210
IS  - 1347-5215 (Electronic)
IS  - 0918-6158 (Linking)
VI  - 34
IP  - 6
DP  - 2011
TI  - Effects of perfluorinated fatty acids with different carbon chain length on fatty 
      acid profiles of hepatic lipids in mice.
PG  - 856-64
AB  - Alterations by perfluorinated fatty acids (PFCAs) with a chain length of 6-9 
      carbons in the fatty acid profile of hepatic lipids of mice were investigated. 
      The characteristic changes caused by all the PFCAs examined were increases in the 
      contents and proportions of oleic acid (18 : 1), palmitoleic acid (16 : 1) and 
      8,11,14-eicosatrienoic acid (20 : 3) in hepatic lipids. Hepatic contents of 
      palmitic acid were also increased by the treatments with the PFCAs. These effects 
      were almost dependent on the hepatic concentrations of PFCA molecules regardless 
      of their carbon chain length. Perfluorooctanoic acid elevated the expressions of 
      mRNA encoding acetyl-CoA carboxylase, fatty acid synthase, malic enzyme, 
      stearoyl-CoA desaturase (SCD) (SCD1 and 2), chain elongase (ELOVL5), Delta6 
      desaturase (Fads2), 1-acylglycerophosphocholine acyltransferase (LPCAT) (LPCAT3). 
      The four PFCAs examined induced microsomal SCD and LPCAT in hepatic 
      concentration-dependent manners regardless of carbon chain length. One linear 
      regression line was confirmed between LPCAT activity and hepatic concentration of 
      PFCA at wide range of the concentration, whereas the induction of SCD was 
      saturable at relatively low concentration of PFCAs. These results suggest (i) 
      that PFCAs with a chain length of 6-9 carbons change the fatty acid profile of 
      hepatic lipids by increasing contents and proportions of 16 : 1, 18 : 1 and 20 : 
      3, (ii) that these alterations in fatty acid profile are caused by up-regulation 
      of SCD, de novo fatty acid synthesis, chain elongase and Delta6 desaturase and (iii) 
      that the mechanism underlying SCD induction is, in part, mediated through 
      peroxisome proliferator-activated receptor alpha.
FAU - Kudo, Naomi
AU  - Kudo N
AD  - Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama, Japan.
FAU - Yamazaki, Tohru
AU  - Yamazaki T
FAU - Sakamoto, Takeshi
AU  - Sakamoto T
FAU - Sunaga, Katsuyoshi
AU  - Sunaga K
FAU - Tsuda, Tadashi
AU  - Tsuda T
FAU - Mitsumoto, Atsushi
AU  - Mitsumoto A
FAU - Kawashima, Yoichi
AU  - Kawashima Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Caprylates)
RN  - 0 (Environmental Pollutants)
RN  - 0 (Fatty Acids)
RN  - 0 (Fatty Acids, Monounsaturated)
RN  - 0 (Fluorocarbons)
RN  - 0 (Isoenzymes)
RN  - 0 (PPAR alpha)
RN  - 0 (RNA, Messenger)
RN  - 209B6YPZ4I (palmitoleic acid)
RN  - 2UMI9U37CP (Oleic Acid)
RN  - 947VD76D3L (perfluorooctanoic acid)
RN  - EC 1.14.19.1 (Stearoyl-CoA Desaturase)
RN  - EC 1.14.19.3 (Linoleoyl-CoA Desaturase)
RN  - EC 2.3.1.- (Acetyltransferases)
RN  - EC 2.3.1.- (Fatty Acid Elongases)
RN  - FC398RK06S (8,11,14-Eicosatrienoic Acid)
SB  - IM
MH  - 8,11,14-Eicosatrienoic Acid/analysis
MH  - Acetyltransferases/genetics/metabolism
MH  - Animals
MH  - Caprylates/analysis/toxicity
MH  - Dose-Response Relationship, Drug
MH  - Environmental Pollutants/analysis/chemistry/*toxicity
MH  - Fatty Acid Elongases
MH  - Fatty Acids/*analysis/biosynthesis/chemistry/*toxicity
MH  - Fatty Acids, Monounsaturated/analysis
MH  - Fluorocarbons/analysis/chemistry/*toxicity
MH  - Gene Expression Regulation, Enzymologic
MH  - Hepatomegaly/*chemically induced/metabolism
MH  - Isoenzymes/genetics/metabolism
MH  - Linoleoyl-CoA Desaturase/genetics/metabolism
MH  - Liver/*chemistry/*drug effects/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Molecular Weight
MH  - Oleic Acid/analysis
MH  - PPAR alpha/metabolism
MH  - RNA, Messenger/metabolism
MH  - Stearoyl-CoA Desaturase/genetics/metabolism
EDAT- 2011/06/02 06:00
MHDA- 2011/10/08 06:00
CRDT- 2011/06/02 06:00
PHST- 2011/06/02 06:00 [entrez]
PHST- 2011/06/02 06:00 [pubmed]
PHST- 2011/10/08 06:00 [medline]
AID - JST.JSTAGE/bpb/34.856 [pii]
AID - 10.1248/bpb.34.856 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2011;34(6):856-64. doi: 10.1248/bpb.34.856.